PFIZER/EISAI ARICEPT PHARMACOECONOMIC ANALYSIS WILL BE READY BY JANUARY LAUNCH; ALZHEIMER'S DRUG HAS ONCE-DAILY DOSING AND NO LIVER ENZYME ELEVATIONS
Aricept cost-effectiveness outcomes and pharmacoeconomic models of Alzheimer's disease are being prepared by Pfizer and will be ready for the January launch of the product. Pfizer/Eisai's Aricept (donepezil, E2020) was approved on Nov. 25 for treatment of mild to moderate dementia of the Alzheimer's type. The cholinesterase inhibitor is the second drug approved for Alzheimer's. Warner-Lambert's cholinesterase inhibitor Cognex (tacrine) was approved in 1993 for the indication. Aricept will be competitively priced to Cognex, Pfizer said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth